Upload
dannon
View
46
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Urine Proteomics in Kawasaki Disease. Pawan Sharma 15 th October 2013. Kawasaki Disease. Uncommonly common systemic vasculitis. 6 months to 4 years age. Significant mortality and morbidity esp with delayed diagnosis. No pathognomic test for early diagnosis. - PowerPoint PPT Presentation
Citation preview
Urine Proteomics in Kawasaki Disease
Pawan Sharma15th October 2013
Kawasaki Disease• Uncommonly common systemic vasculitis.• 6 months to 4 years age.• Significant mortality and morbidity esp with delayed
diagnosis.• No pathognomic test for early diagnosis.
GOAL
To discover and validate diagnostic markers of KD in a prospective cohort..
Study participants• Over 39 months in Tertiary care hospital.• Approved by Boston Children’s Hospital
Committee.• Patients under the age of 18 with possible
diagnosis of KD.• Exclusion criteria: neoplastic, renal or urologic
disease.• Total patients mentioned 236 (234).
Study design • Discovery phase.• Validation phase:
First cohort based on possible KD, but before determination of final diagnosis.
Second cohort utilized serum specimens collected as a part of Pediatric Heart Network Study of KD.
Out come measures• Paediatric Rheumatologist • Use of Published Diagnostic Criteria for KD.• Atypical KD was established using American Heart
association guideline.
DF candidate diagnostic marker• Analysed 15 patients.• 6 KD patients (3 with and 3 without Coronary heart
disease).• 6 non-KD patients (2 non specific, 3 adeno and 1
Pyelonephritis).• 3 matched specimen from treated patients with KD
(after 1 month).• 190 proteins specific to KD.• Meprin A and Filamin C chosen.
Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease
EMBO Molecular MedicineVolume 5, Issue 2, pages 210-220, 20 DEC 2012 DOI: 10.1002/emmm.201201494http://onlinelibrary.wiley.com/doi/10.1002/emmm.201201494/full#fig1
Validation • Prospectively measured concentration in urine.• Investigators blinded to Final diagnosis.• Mean age 3 years.• 53 (49%) final diagnosis of KD.• All treated with IVIg and Aspirin, 30% required
repeat treatment.• All studied patients received a Final Outcome.
Table 2. Final diagnosis of the 107 study patients
Final diagnosis Number of patients
Kawasaki disease 53 (49%)
Viral syndrome 33 (61%)
Adenovirus 6
Serum sickness 3
Pyelonephritis 2
group A streptococcal pharyngitis 2
Cytomegalovirus 1
Epstein-Barr virus 1
Group A streptococcal pharyngitis 1
Lyme disease 1
Otitis media 1
Pneumonia 1
Respiratory syncytial virus 1
Systemic arthritis 1
KD Non KD
Filamin C 19.2 3.7
Meprin A 50.2 5.6
Atypical KD Non KD
Filamin C 17 3.7
Meprin A 41.5 5.6
Mean values
Blinded case control study
Response to treatment
2nd Cohort• 112 archived samples collected from KD patient
analysed.• Compared them with Non-KD febrile illness.• Serum samples used.• Results were:
KD Non KD
Filamin C 217 6.6
Meprin A 1363 14.8
Mouse model
What do we think• Clear question for study address?• Was there a comparison with appropriate
standard? • Did all patients get diagnostic test and reference
standard?• Could the result have been influenced?• Is disease status clearly described?• Were methods described in clear details?• What are the results?• Can the results be applied to our patients?
Summary• Potential approaches for improving diagnosis.• Discover phase: very small group.• Mechanism of how this markers accumulate shall
be important direction for future work.• Limitations: Renal or Urologic disease, sever
dehydration or ? Shock.
• Thank you!
The Receiver Operating Characteristic Curve.• true positive rate (Sensitivity) is plotted in function of the
false positive rate (100-Specificity) for different cut-off points.
• Each point on the ROC curve represents a sensitivity/specificity pair corresponding to a particular decision threshold.
• A test with perfect discrimination has a ROC curve that passes through the upper left corner (100% sensitivity, 100% specificity). Therefore the closer the ROC curve is to the upper left corner, the higher the overall accuracy of the test .
ROC Chart